ArticleMedeniyet medical journal2025
Short- and Long-Term Statin Persistence and Determinants in Patients Initiating Statin Therapy.
Article in Medeniyet medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite the established efficacy of statins in reducing major cardiovascular events and mortality, rates of statin persistence remain low. This study aimed to assess short- and long-term statin persistence rates and identify factors influencing persistence in patients initiating statin therapy. Methods: A retrospective, observational, clinical study was conducted, enrolling a consecutive total of 903 patients aged 18 years and older (692 female, 211 male, mean age: 60.74 ± 11.70 years) who had initiated statin therapy between January 1, 2016, and January 1, 2017. Short-term (2018) and long-term (2023) statin persistence statuses were determined. Groups persisting and non-persisting with statin therapy were compared for demographic characteristics; presence of cardiometabolic diseases such as diabetes mellitus (DM), coronary artery disease (CAD), and hypertension (HT); statin therapy intensities; and indications for statin initiation (primary or secondary prevention) for both time periods. Results: The study included 903 patients with a mean age of 60.7±11.7 years and a female predominance of 76.6%. In 2018, 498 (55.1%) patients continued statin therapy, while 405 (44.9%) discontinued. In 2023, excluding 36 cases with death (18 cases were among those continuing statin treatment, and 18 cases were who did not continue). Four hundred and forty-eight (51.7%) patients persisted with statin therapy, while 419 (48.3%) discontinued. Statin non-persistence was more frequent in patients initiated on statins for primary prevention (p<0.01) and more frequent in those under 45 years old (p=0.028 and p=0.036, respectively), while it was less common in patients with HT, DM, and CAD (all p<0.01). Conclusions: The study reveals the low and declining rates of statin persistence in patients initiating statin therapy, both in the short and long term. Furthermore, persistence rates are lower in younger patients and those initiated on statins for primary prevention compared to those with established cardiovascular risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.